FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease

[1]  J. Cummings,et al.  Repurposed agents in the Alzheimer’s disease drug development pipeline , 2020, Alzheimer's Research & Therapy.

[2]  L. Schneider,et al.  The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier coh , 2018, Alzheimer's & dementia.

[3]  Jianhua Shi,et al.  Relevance of Phosphorylation and Truncation of Tau to the Etiopathogenesis of Alzheimer’s Disease , 2018, Front. Aging Neurosci..

[4]  S. Bachurin,et al.  Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends , 2017, Medicinal research reviews.

[5]  L. Buée,et al.  Tau deletion promotes brain insulin resistance , 2017, The Journal of experimental medicine.

[6]  F. J. Livesey,et al.  Extracellular Monomeric and Aggregated Tau Efficiently Enter Human Neurons through Overlapping but Distinct Pathways , 2018, Cell reports.

[7]  G. Cantone,et al.  PAN-TAU ANTIBODY BIIB076 EXHIBITS PROMISING SAFETY AND BIOMARKER PROFILE IN CYNOMOLGUS MONKEY TOXICITY STUDY , 2017, Alzheimer's & Dementia.

[8]  J. Cummings,et al.  Alzheimer's disease drug development pipeline: 2017 , 2017, Alzheimer's & dementia.

[9]  Stanislav Katina,et al.  Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial , 2017, The Lancet Neurology.

[10]  R. P. Maguire,et al.  Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study , 2016, Alzheimer's & dementia.

[11]  A. Murzin,et al.  Cryo-EM structures of Tau filaments from Alzheimer’s disease brain , 2017, Nature.

[12]  T. Hromádka,et al.  Human Truncated Tau Induces Mature Neurofibrillary Pathology in a Mouse Model of Human Tauopathy. , 2016, Journal of Alzheimer's disease : JAD.

[13]  Carlos Pineda,et al.  Assessing the Immunogenicity of Biopharmaceuticals , 2016, BioDrugs.

[14]  Fei Liu,et al.  Tau and neurodegenerative disease: the story so far , 2016, Nature Reviews Neurology.

[15]  E. Mandelkow,et al.  Tau in physiology and pathology , 2015, Nature Reviews Neuroscience.

[16]  D. Louis Collins,et al.  Assessing atrophy measurement techniques in dementia: Results from the MIRIAD atrophy challenge , 2015, NeuroImage.

[17]  D. Mann,et al.  Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau , 2015, Acta Neuropathologica.

[18]  N. Petrovsky,et al.  A fresh perspective from immunologists and vaccine researchers: Active vaccination strategies to prevent and reverse Alzheimer's disease , 2015, Alzheimer's & Dementia.

[19]  E. Liu,et al.  Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[20]  G. Parry,et al.  Human secreted tau increases amyloid-beta production , 2015, Neurobiology of Aging.

[21]  D. Holtzman,et al.  Anti-tau antibody reduces insoluble tau and decreases brain atrophy , 2015, Annals of clinical and translational neurology.

[22]  N. Zilka,et al.  First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model , 2014, Alzheimer's Research & Therapy.

[23]  N. Zilka,et al.  Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer’s disease , 2014, Alzheimer's Research & Therapy.

[24]  L. Collin,et al.  Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer's disease. , 2014, Brain : a journal of neurology.

[25]  J. Karlawish,et al.  The A4 Study: Stopping AD Before Symptoms Begin? , 2014, Science Translational Medicine.

[26]  P. Mecocci,et al.  Clinical trials and late‐stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014 , 2014, Journal of internal medicine.

[27]  Nick C Fox,et al.  Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.

[28]  F. van Leuven,et al.  Efficacy and Safety of A Liposome-Based Vaccine against Protein Tau, Assessed in Tau.P301L Mice That Model Tauopathy , 2013, PloS one.

[29]  Michel Goedert,et al.  Tau pathology and neurodegeneration , 2013, The Lancet Neurology.

[30]  C. Jack,et al.  Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study , 2012, The Lancet Neurology.

[31]  E. Siemers,et al.  Safety profile of Alzheimer's disease populations in Alzheimer's Disease Neuroimaging Initiative and other 18-month studies , 2012, Alzheimer's & Dementia.

[32]  Bruce Fischl,et al.  Within-subject template estimation for unbiased longitudinal image analysis , 2012, NeuroImage.

[33]  K. Jellinger,et al.  Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature , 2012, Journal of neuropathology and experimental neurology.

[34]  D McDaid,et al.  The economic impact of dementia in Europe in 2008—cost estimates from the Eurocode project , 2011, International journal of geriatric psychiatry.

[35]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[36]  R. Mayeux,et al.  Epidemiology of Alzheimer disease , 2011, Nature Reviews Neurology.

[37]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[38]  Bruce Fischl,et al.  Highly accurate inverse consistent registration: A robust approach , 2010, NeuroImage.

[39]  Nick C Fox,et al.  Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders , 2009, Current Alzheimer research.

[40]  N. Zilka,et al.  Misfolded tau protein and disease modifying pathways in transgenic rodent models of human tauopathies , 2009, Acta Neuropathologica.

[41]  J. Barnes,et al.  A comparison of methods for the automated calculation of volumes and atrophy rates in the hippocampus , 2008, NeuroImage.

[42]  P. Filipcik,et al.  Truncated tau from sporadic Alzheimer's disease suffices to drive neurofibrillary degeneration in vivo , 2006, FEBS letters.

[43]  Nick C Fox,et al.  Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial , 2005, Neurology.

[44]  Robert W Berry,et al.  Tau, tangles, and Alzheimer's disease. , 2005, Biochimica et biophysica acta.

[45]  A. Tzankov,et al.  Age‐related loss of naïve T cells and dysregulation of T‐cell/B‐cell interactions in human lymph nodes , 2005, Immunology.

[46]  Mark W. Woolrich,et al.  Advances in functional and structural MR image analysis and implementation as FSL , 2004, NeuroImage.

[47]  D. Bennett,et al.  Early N-Terminal Changes and Caspase-6 Cleavage of Tau in Alzheimer's Disease , 2004, The Journal of Neuroscience.

[48]  M. Mattson.  Pathways towards and away from Alzheimer's disease , 2004, Nature.

[49]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[50]  Stephen M. Smith,et al.  Accurate, Robust, and Automated Longitudinal and Cross-Sectional Brain Change Analysis , 2002, NeuroImage.

[51]  J. Kabat,et al.  Molecular characterization of the minimal protease resistant tau unit of the Alzheimer's disease paired helical filament. , 1993, The EMBO journal.

[52]  C. Milstein,et al.  Difference between the tau protein of Alzheimer paired helical filament core and normal tau revealed by epitope analysis of monoclonal antibodies 423 and 7.51. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[53]  H. Wiśniewski,et al.  Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. , 1986, Proceedings of the National Academy of Sciences of the United States of America.